Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs)
- 1 January 2012
- journal article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 2 (5), 448-458
- https://doi.org/10.7150/thno.3931
Abstract
Neuroendocrine tumors (NETs) possess unique features including expression of peptide hormone receptors as well as the capacity to concentrate and take up precursor forms of amines and peptides making hormones that are stored in secretory granules within the tumor cells (APUD). The expression of somatostatin receptors on tumor cells have been widely explored during the last two decades starting with 111In-DTPA-Octreotide as an imaging agent followed by 68Ga-DOTATOC/TATE positron emission tomography scanning. The new generation of treatment includes 90Yttrium-DOTATOC/DOTATATE as well as 177Lutetium-DOTATOC/DOTATATE/DOTANOC treatment of various subtypes of NETs. The objective response rate by these types of PRRT is in the range of 30-45% objective responses with 5-10% grade 3/4 toxicity mainly hematologic and renal toxicity. The APUD mechanism is another unique feature of NETs which have generated an interest over the last two decades to develop specific tracers including 11C-5HTP, 18F-DOPA and 11C-hydroxyefedrin. These radioactive tracers have been developed in centres with specific interest in NETs and are not available everywhere. 111In-DTPA-Octreotide is still the working horse in diagnosis and staging of metastatic NETs, but will in the future be replaced by 68Ga-DOTATOC/DOTATATE PET/CT scanning which provide higher sensitivity and specificity and is also more convenient for the patient because it is a one-stop-procedure. Both 90Yttrium-DOTATOC/DOTATATE as well as 177Lutetium-DOTATOC/DOTATATE are important new therapies for malignant metastatic NETs. However, the precise role in the treatment algorithm has to be determined in forthcoming randomized trials.Keywords
This publication has 42 references indexed in Scilit:
- Molecular Theranostics: A Primer for the Imaging ProfessionalAmerican Journal of Roentgenology, 2011
- The Epidemiology of Gastroenteropancreatic Neuroendocrine TumorsEndocrinology and Metabolism Clinics of North America, 2011
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- The Diagnosis and Medical Management of Advanced Neuroendocrine TumorsEndocrine Reviews, 2004
- Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targetingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993
- Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.1992
- LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATINThe Lancet, 1989
- THE CYTOCHEMISTRY AND ULTRASTRUCTURE OF POLYPEPTIDE HORMONE-PRODUCING CELLS OF THE APUD SERIES AND THE EMBRYOLOGIC, PHYSIOLOGIC AND PATHOLOGIC IMPLICATIONS OF THE CONCEPTJournal of Histochemistry & Cytochemistry, 1969